David Merryman
-
Emily Days wins Rosalind Franklin Society Special Award in Science for contributions to the journal ASSAY and Drug Development Technologies
Days’ work to identify highly potent and selective 5-HT2B antagonists was recognized by the Rosalind Franklin Society Read MoreAug. 28, 2024
-
Vanderbilt scientists make headway in drug development to cure pulmonary arterial hypertension
Research by David Merryman and Craig Lindsley has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects. The article, “Development of a Peripherally Restricted… Read MoreSep. 13, 2023